Janux Therapeutics, Inc.

JANX · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders1.5%

Institutions101.4%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$10.00M	$10.59M	$8.61M	$3.64M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$157.67M	-$98.85M	-$67.09M	-$32.93M
Operating income as a percentage of revenue.	-1576.7%	-933.6%	-779.0%	-905.4%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$113.63M	-$68.99M	-$63.06M	-$32.67M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.00	$-1.00	$-1.00	$-1.39
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.00	$-1.00	$-1.00	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$52.33M	$430.61M	$51.43M	$35.58M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.00B	$1.06B	$364.01M	$379.82M
Everything the company owes — debt, unpaid bills, and other obligations.	$44.74M	$38.73M	$43.27M	$13.50M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$956.82M	$1.02B	$320.74M	$366.33M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$82.23M	-$43.81M	-$42.92M	-$16.98M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.04M	$359000	$6.45M	$1.48M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$83.28M	-$44.17M	-$49.37M	-$18.46M

	You	Peer avg
P/E	–	16.0
Revenue Growth	–	+4325.8%
ROE	-10.7%	16.2%

Janux Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison